Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callNasdaq· January 28, 2026

Extreme Networks EXTR Q2 2026 Earnings Transcript

View original at nasdaq.com
Extreme Networks EXTR Q2 2026 Earnings Transcript Image source: The Motley Fool. DATE Jan. 28, 2026 at 8:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Edward B…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Extreme is growing 3x faster than largest competitors in enterprise networking

    80% confidence
  • Platform One bookings in Q2 were twice the target amount

    80% confidence
  • Organizational agility is a core competency for component cost management

    80% confidence
  • Price increases had minimal effect on Q2 results

    80% confidence
  • Extreme is the only player in networking space that can deliver data sovereign solution

    80% confidence
  • Tariff changes are a way of life with minimal current business impact

    80% confidence
  • Extreme Networks is always looking at different acquisition assets but has nothing to comment on regarding Ruckus speculation

    80% confidence
  • Extreme Networks is the only vendor that delivers true cloud choice

    80% confidence
  • Extreme Networks is the only networking vendor that has an agentic AI platform

    80% confidence
  • Platform One subscription bookings were the strongest on record and more than doubled internal targets in Q2

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com